Scholarlink

<p>This retrospective study investigated the impact of metformin initiation on 24-hour urine parameters in patients with diabetes with urolithiasis. Utilizing the Medicare-Litholink database, we analyzed 427 patients who started metformin between two 24-hour urine collections conducted less than 18 months apart. To isolate the effect of metformin on urinary parameters as a surrogate marker of stone growth, we excluded patients taking other oral hypoglycemics or medications known to alter urine composition. Our longitudinal analysis revealed no statistically significant changes in key urinary parameters, including supersaturation of calcium oxalate, supersaturation calcium phosphate, and supersaturation of uric acid. Urine volume showed a significant, albeit clinically minor, increase (2.1 to 2.2&#xa0;L/day, <i>p</i> = 0.0074). Time-dependent analysis comparing short-term (&lt; 100 days) and long-term (&gt; 296 days) metformin use also showed no significant impact on urine chemistry. Similarly, when controlling dosage of metformin (<InlineEquation ID="IEq1"> <EquationSource Format="TEX">\(\:\le\:\)</EquationSource> </InlineEquation>1000&#xa0;mg/day or &gt; 1000&#xa0;mg/day) we found no significant impact on urine chemistry. These findings suggest that metformin use is not significantly associated with reduced urinary stone risk factors in patients with diabetes and urolithiasis, thus, failing to support its use among urolithiasis patients with new onset diabetes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of 24-Hour urine parameters before and after initiation of Metformin in patients with diabetes and urolithiasis: A retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Taylor Crook,
  • Ian Ong,
  • Yezan Hadidi,
  • Aymon Ali,
  • John M. Hollingsworth,
  • Mary K. Oerline,
  • Vahakn B. Shahinian,
  • Sara Best,
  • Ryan S. Hsi,
  • Joseph J. Crivelli,
  • Ralph V. Clayman

摘要

This retrospective study investigated the impact of metformin initiation on 24-hour urine parameters in patients with diabetes with urolithiasis. Utilizing the Medicare-Litholink database, we analyzed 427 patients who started metformin between two 24-hour urine collections conducted less than 18 months apart. To isolate the effect of metformin on urinary parameters as a surrogate marker of stone growth, we excluded patients taking other oral hypoglycemics or medications known to alter urine composition. Our longitudinal analysis revealed no statistically significant changes in key urinary parameters, including supersaturation of calcium oxalate, supersaturation calcium phosphate, and supersaturation of uric acid. Urine volume showed a significant, albeit clinically minor, increase (2.1 to 2.2 L/day, p = 0.0074). Time-dependent analysis comparing short-term (< 100 days) and long-term (> 296 days) metformin use also showed no significant impact on urine chemistry. Similarly, when controlling dosage of metformin ( \(\:\le\:\) 1000 mg/day or > 1000 mg/day) we found no significant impact on urine chemistry. These findings suggest that metformin use is not significantly associated with reduced urinary stone risk factors in patients with diabetes and urolithiasis, thus, failing to support its use among urolithiasis patients with new onset diabetes.